関連する実験動画
Updated: Jul 8, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
アンジオテンシンIIアンタゴニストは,心房細動における電気的改造を防ぐ
H Nakashima1, K Kumagai, H Urata
1Second Department of Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan. kxk@fukuoka-u.ac.jp
Circulation
|June 7, 2000
まとめ
アンジオテンシンII (Ang II) 阻害は,心房の有効な耐火期の縮小を阻害することによって,心房の電気再構築を防ぐ. これは,Ang II 阻害が心房細動に対する治療戦略である可能性があることを示唆しています.
科学分野:
- 心血管生理学 心血管の生理学
- 電気生理学 電気生理学
背景:
- アンジオテンシンII (Ang II) 形成阻害は,心血管の保護を提供します.
- 心房の電気再構築におけるAng IIの特定の役割は不明である.
研究 の 目的:
- カンデサルタンとカプトプリルが心房の電気再構築に与える影響を調査する.
- Ang II が,高速ペースでの心房効果的耐火期 (AERP) に影響するかどうかを判断する.
主な方法:
- 犬は急激な心房ペース (800bpmで180分) を受けました.
- グループには塩溶液,カンデサルタン,カプトプリル,またはAng IIの輸液が投与された.
- アトリアル有効耐火期 (AERP) は,ペースアップ前後を測定した.
主要な成果:
- 塩素とAng II群では,AERPの縮小が顕著であった.
- カンデサルタンとカプトプリルは,AERP縮小を完全に抑制しました.
- AERPの適応率は,カンデサルタンとキャプトプリルで維持された.
結論:
- 固有のAng II阻害は,急速な心房ペースでAERPの縮小を防ぐ.
- Ang IIは,心房の電気再構成メカニズムに関与しています.
- Ang IIの阻害は,ヒトの心房細動に対する治療上の利点を提供することがあります.
関連する概念動画
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:25Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...